(Q54561460)

31 May 2018

title

Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis. (English)

1 reference

31 May 2018

1 reference

Katsuaki Kanbe

1

1 reference

31 May 2018

Qian Chen

series ordinal

2

1 reference

31 May 2018

Atsushi Nakamura

series ordinal

3

1 reference

31 May 2018

Kaori Hobo

series ordinal

4

1 reference

31 May 2018

publication date

10 September 2011

1 reference

31 May 2018

published in

Clinical Rheumatology

1 reference

31 May 2018

volume

30

1 reference

31 May 2018

issue

11

1 reference

31 May 2018

page(s)

1407-1413

1 reference

31 May 2018

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Interleukin 6: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1833-Z

Therapeutic criteria in rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

12 December 2020

Interleukin-6: an overview

1 reference

12 December 2020

Interleukin-6 family of cytokines and gp130

1 reference

12 December 2020

10.1007/S10067-011-1833-Z

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018